Loading
A phase 3 trial of Atezolizumab, Bevacizumab, Pemetrexed and Enzalutamide in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) is a phase 3 interventional study registered as NCT05112965 by Hoffmann-La Roche, with 49 participants enrolled, started 2021-12-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: Atezolizumab, Bevacizumab, Pemetrexed, Paclitaxel and Enzalutamide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flatiron Health (Roche), Atezolizumab, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pemetrexed, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/